EuroBiotech:​​ ​​More​​ ​​Articles​​ ​​of​​ ​​Note

A pile of newspapers

> Novo Nordisk paid Ablynx a €1 million ($1.1 million) milestone. The milestone, the first paid out under the deal the partners struck one year ago, follows the advance of a program to develop multispecific therapeutic proteins based on single-domain antibody fragments. Ablynx is aiming to get the candidate into the clinic in 2018. Release

> BerGenBio posted data from a phase 1/2 trial of its Axl kinase inhibitor in patients with advanced non-small cell lung cancer. Two of the eight patients who received the drug as a monotherapy had stable disease for at least six months. No patients experienced grade 3 or 4 adverse events. The next step is to test the drug in combination with Tarceva in EFGR mutant patients. Release

> A1M Pharma took another step toward moving its preeclampsia program into the clinic. The Swedish biotech now has maximum tolerated dose data from two animal models, teeing it up to assess the effect of repeat administrations. A1M expects to have data from the tests early next year and start GLP-compliant toxicology studies in the second quarter. Release

Whitepaper Download

Reducing the Complexity and Costs of Channel Planning and Logistics

How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business.

> TopiVert secured clearance to trial its treatment of dry eye syndrome. The narrow spectrum kinase inhibitor specialist plans to start a phase 1/2 trial of its candidate in January. Release

> Shares in Genticel rose more than 125% after its multivalent vaccine partnership with Serum Institute of India progressed. The reengineered adenylate cyclase, GTL003, has cleared the last preclinical milestone, triggering a $1.2 million (€1.1 million) milestone and setting Serum Institute up to advance the candidate toward the clinic. Release

> Innate Pharma posted data from a dose-ranging study of monalizumab in patients with advanced gynecologic malignancies. The study gave monalizumab monotherapy to 18 patients. Safety data generated in that part of the phase 1/2 trial have encouraged Innate to start enrolling a 98-person expansion cohort and giving them the recommended dose. Release

Suggested Articles

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.  

Blocking tau appears to be just as fruitless as clearing amyloid buildup when it comes to helping Alzheimer’s disease patients.